PMID- 33343360
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201222
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Therapeutic Potential of Exosomes in Pulmonary Fibrosis.
PG  - 590972
LID - 10.3389/fphar.2020.590972 [doi]
LID - 590972
AB  - Pulmonary fibrosis is closely associated with the recruitment of fibroblasts from 
      capillary vessels with damaged endothelial cells, the epithelial mesenchymal 
      transition (EMT) of type II alveolar epithelial cells, and the transformation of 
      fibroblasts to myofibroblasts. Recent studies suggest that EMT is a key factor in 
      the pathogenesis of pulmonary fibrosis, as the disruption of EMT-related effector 
      molecules can inhibit the occurrence and development of PF. With the numerous 
      advancements made in molecular biology in recent years, researchers have 
      discovered that exosomes and their cargos, such as miRNAs, lncRNAs, and proteins, 
      can promote or inhibit the EMT, modulate the transformation of fibroblasts into 
      myofibroblasts, contribute to the proliferation of fibroblasts and promote 
      immunoregulatory and mitochondrial damage during pulmonary fibrosis. Exosomes are 
      key factors regulating the differentiation of bone marrow mesenchymal stem cells 
      (BMSCs) into myofibroblasts. Interestingly, exosomes derived from BMSCs under 
      pathological and physiological conditions may promote or inhibit the EMT of type 
      II alveolar epithelial cells and the transformation of fibroblasts into 
      myofibroblasts to regulate pulmonary fibrosis. Thus, exosomes may become a new 
      direction in the study of drugs for the treatment of pulmonary fibrosis.
CI  - Copyright (c) 2020 Xie and Zeng.
FAU - Xie, Linshen
AU  - Xie L
AD  - West China School of Public Health and West China Fourth Hospital, Sichuan 
      University, Chengdu, China.
FAU - Zeng, Ye
AU  - Zeng Y
AD  - Institute of Biomedical Engineering, West China School of Basic Medical Sciences 
      and Forensic Medicine, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201204
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7746877
OTO - NOTNLM
OT  - bone marrow mesenchymal stem cell
OT  - epithelial mesenchymal transition
OT  - exosome
OT  - myofibroblast
OT  - pulmonary fibrosis
OT  - type II alveolar epithelial cell
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
PMCR- 2020/12/04
CRDT- 2020/12/21 06:04
PHST- 2020/08/04 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/12/21 06:04 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
PHST- 2020/12/04 00:00 [pmc-release]
AID - 590972 [pii]
AID - 10.3389/fphar.2020.590972 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Dec 4;11:590972. doi: 10.3389/fphar.2020.590972. 
      eCollection 2020.